What unifies Huntington's, spinocerebellar ataxia and myotonic dystrophy? Ness Bermingham's new startup looks to drug that

Amber Tong

Ness Bermingham’s latest venture brings throwbacks to some of his earliest work in biopharma. Part of his PhD work at Imperial College London revolved around …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

What unifies Huntington's, spinocerebellar ataxia and myotonic dystrophy? Ness Bermingham's new startup looks to drug that

Amber Tong

Sign up to read this article for free.

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Acadia snaps up an essential tremor drug after field's summer setbacks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

What uni­fies Hunt­ing­ton's, spin­ocere­bel­lar atax­ia and my­oton­ic dy­s­tro­phy? Ness Berming­ham's new start­up looks to drug that

Amber Tong

Sign up to read this article for free.

more like this

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

What unifies Huntington's, spinocerebellar ataxia and myotonic dystrophy? Ness Bermingham's new startup looks to drug that

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Acadia snaps up an essential tremor drug after field's summer setbacks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks